Overview

Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation

Status:
Recruiting
Trial end date:
2022-12-10
Target enrollment:
Participant gender:
Summary
Post-inflammatory hyperpigmentation is a common pigmentary skin disorder that is refractory to treatment. The treatment for postinflammatory hyperpigmentation is limited. Recent studies have shown that the topical skin care product cysteamine cream has a significant decrease in melanin index without obvious side effects in other dark spots such as melasma. The goal of this study is to determine the safety and efficacy of topical cysteamine in the treatment of post-inflammatory hyperpigmentation.
Phase:
N/A
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborator:
Scientis Pharma SA
Treatments:
Cysteamine